True Private Wealth Advisors Galectin Therapeutics Inc Transaction History

True Private Wealth Advisors

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2021 May 12, 2021	SELL	$1.96 - $2.57 $1,960 - $2,570	-1,000 Closed	0 $0
Q3 2020 Oct 09, 2020	BUY	$2.53 - $3.64 $2,530 - $3,640	1,000 New	1,000 $2,000

9.35M

982K

2.7K

Ticker GALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,426,000
Market Cap $168M
Description
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...

Get notified when there are updates to the investment portfolio of True Private Wealth Advisors, based on Form 13F filings with the SEC.

Stay updated on True Private Wealth Advisors with notifications on news.